Biotech News

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

Fulgent Genetics, Inc. (FLGT)Fulgent Genetics, Inc.Company update

EL MONTE, Calif. --(BUSINESS WIRE)--Mar. 17, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a

Related news

Fulgent Genetics, Inc.

Precision Medicine Business Fulgent Genetics operates a laboratory-services business alongside a therapeutic-development portfolio. The company aims to combine diagnostic capabilities with drug development to become an integrated precision-medicine organization. Laboratory Services Fulgent provides technical laboratory testing and...

Recent company news

Stock data

Close
18.55 USD
Market cap
531.09M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States